EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Widespread Pain Moderates the Response to Centrally‐Acting Therapies in an Observational Cohort of Patients With Urologic Chronic Pelvic Pain Syndrome: A MAPP Research Network Study

Andrew Schrepf, Kenneth Locke, Robert Moldwin, David A Williams, Sara Till, John Farrar, J Richard Landis, Frank Tu, Larissa Rodriguez, Henry Lai, Bruce Naliboff, Jason Kutch und 9 weitere

Neurourology and Urodynamics · 2025

DOI: 10.1002/nau.70068 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Neurourology and Urodynamics, 2025. Verfasst von Andrew Schrepf und 20 weiteren Autor:innen. Beteiligte Einrichtung: University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Pelvic Pain, Chronic Pain, Physical Therapy Modalities. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, Funding for the MAPP Research Network was obtained under a cooperative agreement from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose Urologic Chronic Pelvic Pain Syndrome (UCPPS) impacts millions of people in the United States but treatment options remain largely unsatisfying. A large number of neurobiological studies from the Multidisciplinary Approach to the study of chronic Pelvic Pain (MAPP) research network and others point to aberrant pain mechanisms in patients with UCPPS and widespread pain, but the clinical significance of widespread pain has been speculative. Materials and Methods In the current exploratory study we investigated whether pain and urologic symptoms responded to centrally‐directed therapies (tricyclic antidepressants/gabapentinoids) versus peripherally‐directed (pelvic floor physical therapy/hydrodistension) therapies depending on the presence or absence of widespread pain when the new treatment was initiated. Results and Conclusions Forty UCPPS patients ( n = 19 widespread) underwent an evaluation of UCPPS symptoms before and after twelve weeks of either centrally‐directed ( n = 16) or peripherally‐directed therapy. Participants were stratified post hoc into widespread (two or more non‐pelvic pain sites + pelvic pain) and localized pain categories. General linear models were used to test the group X treatment interaction effect, adjusting for age, sex, and baseline outcome levels. On average, patients with widespread pain receiving centrally‐directed therapies improved more than six points on the 0–28 Pelvic Pain Severity scale, while those with localized pain showed no average improvement (interaction p = 0.005). Similar effects were observed for the bladder symptom impact score (interaction p = 0.011) but not urologic symptom severity (interaction p = 0.72). While these findings are exploratory, they provide preliminary evidence for phenotype X treatment interactions in UCPPS and should be followed by confirmatory studies. Trial Registration ClinicalTrials.gov Identifier: NCT02514265—MAPP Research Network: Trans‐MAPP Study of Urologic Chronic Pelvic Pain: Symptom Patterns Study (SPS). ClinicalTrials.gov Identifier: NCT02898220—Trans‐MAPP Study of Urologic Chronic Pelvic Pain: Control Study Protocol.xs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pelvic PainChronic PainPhysical Therapy ModalitiesHumansFemaleMaleMiddle AgedAdultTreatment OutcomePain MeasurementGabapentin

Stichwörter der Autor:innen

amitriptylinechronic paininterstitial cystitispelvic floorprostatitis

Substanzen

Gabapentin

Autor:innen und Institutionen

  • University of Michigan, Ann Arbor, Michigan, USA.
  • Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Zucker School of Medicine, Hofstra/Northwell, Hempstead, New York, USA.
  • NorthShore University HealthSystem and Pritzker School of Medicine University of Chicago, Chicago, Illinois, USA.
  • Weill Cornell Medicine, New York, New York, USA.
  • Washington University School of Medicine, St Louis, Missouri, USA.

Förderung

  • NIDDK NIH HHS
  • Funding for the MAPP Research Network was obtained under a cooperative agreement from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),…

Zitieren

APA

Schrepf, A., Locke, K., Moldwin, R., Williams, D. A., Till, S., Farrar, J., Richard Landis, J., Tu, F., Rodriguez, L., Lai, H., Naliboff, B., Kutch, J., Harte, S. E., Harris, R. E., Kreder, K. J., Spitznagle, T., McKernan, L., Yang, C., Quentin Clemens, J., …, & Clauw, D. J. (2025). Widespread Pain Moderates the Response to Centrally‐Acting Therapies in an Observational Cohort of Patients With Urologic Chronic Pelvic Pain Syndrome: A MAPP Research Network Study. Neurourology and Urodynamics. https://doi.org/10.1002/nau.70068

Vancouver

Schrepf A, Locke K, Moldwin R, Williams DA, Till S, Farrar J, et al. Widespread Pain Moderates the Response to Centrally‐Acting Therapies in an Observational Cohort of Patients With Urologic Chronic Pelvic Pain Syndrome: A MAPP Research Network Study. Neurourology and Urodynamics. 2025. doi:10.1002/nau.70068

BibTeX
@article{Schrepf2025,
  author = {Schrepf, Andrew and Locke, Kenneth and Moldwin, Robert and Williams, David A and Till, Sara and Farrar, John and Richard Landis, J and Tu, Frank and Rodriguez, Larissa and Lai, Henry and Naliboff, Bruce and Kutch, Jason and Harte, Steven E and Harris, Richard E and Kreder, Karl J and Spitznagle, Tracy and McKernan, Lindsey and Yang, Claire and Quentin Clemens, J and Mullins, Chris and Clauw, Daniel J},
  title = {Widespread Pain Moderates the Response to Centrally‐Acting Therapies in an Observational Cohort of Patients With Urologic Chronic Pelvic Pain Syndrome: A MAPP Research Network Study},
  journal = {Neurourology and Urodynamics},
  year = {2025},
  doi = {10.1002/nau.70068}
}
Kostenlos starten →